Lennox Gastaut Syndrome News and Research

RSS

Lennox-Gastaut syndrome (LGS) is a severe type of epilepsy characterized by many types of seizures, mainly drop and stiffening seizures. LGS can be a result of malformations in the brain, head injury, perinatal asphyxia, infection in the central nervous system, and inherited metabolic or degenerative disorders.

CureSHANK to award $250,000 for stimulating research on SHANK3-related epilepsy

CureSHANK will award a total of $250,000 aimed at stimulating research on SHANK3-related epilepsy, prevalent in PMS patients.

30 Nov 2023

High-dose CBD fails to relieve pain in knee osteoarthritis patients

Cannabidiol (CBD) is marketed by some suppliers as a painkiller, e.g. for osteoarthritis of the knee. Animal experiments have shown that the substance, which is extracted from the hemp plant, has an anti-inflammatory and pain-relieving effect in arthritis.

14 Nov 2023

Unlocking the potential of the ketogenic diet: studies reveal health benefits

Researchers reported on the effects of the ketogenic diet (KD) on various aspects of metabolic and endocrinal health.

20 Sep 2023

What is the impact of oral cannabidiol on simulated driving?

Researchers assessed the impact of cannabidiol on the driving performance of humans.

6 Mar 2023

CBD may reduce the adverse effects of anti-seizure drugs in people with epilepsy

Artisanal (non-pharmaceutical) cannabidiol (CBD) products have become popular in recent years for their apparent therapeutic effects. CBD — a naturally occurring compound of the cannabis plant legally derived from hemp — is used widely as a naturopathic remedy for a number of health conditions, including epilepsy and seizure disorders.

11 Aug 2021

FDA warns two companies for illegal marketing of unapproved CBD products

The U.S. Food and Drug Administration has issued warning letters to two companies for selling products labeled as containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).

22 Mar 2021

FDA issues warning letters to companies illegally selling unapproved CBD products

Today, the U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).

22 Dec 2020

FDA approves CBD oral solution for treatment of seizures related to tuberous sclerosis complex

Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.

31 Jul 2020

Young Epilepsy welcomes NICE’s approval of CBD as treatment for children with epilepsy

Responding to the publication of the NICE guidelines on cannabis-based medicinal products and the approval of CBD as a treatment, Mark Devlin, Chief Executive of Young Epilepsy, said: Living with epilepsy can have a significant impact on the lives of children, young people and their families.

11 Nov 2019

Study may help explain effects of cannabidiol on seizure frequency in Lennox-Gastaut patients

Results from a study published in the British Journal of Clinical Pharmacology may help explain why cannabidiol--a chemical component of marijuana with no psychoactive properties--reduces the frequency of seizures in patients with a severe form of epilepsy.

7 Nov 2019

Researchers study cannabis dosage to reduce seizures in children with severe epilepsy

Medicinal cannabis oil containing both cannabidiol and a small amount of THC can reduce or end seizures in children with severe, drug-resistant epilepsy, a study by the University of Saskatchewan, Canada has found.

8 Jul 2019

Cannabinoids hold promise in treating children with epilepsy

In recent years, cannabinoids--the active chemicals in medical marijuana-- have been increasingly touted as a potential treatment for a range of neurological and psychiatric disorders. In a Developmental Medicine & Child Neurology review, investigators compare their efficacy with antiepileptic drugs for children with epilepsy.

7 Nov 2018

The pluses and minuses of allowing medical marijuana at school

Every school day at noon, Karina Garcia drives to her son’s South San Francisco high school to give him a dose of cannabis oil to prevent potentially life-threatening seizures.

30 Aug 2018

FDA approves cannabis based drug for severe form of epilepsy

The U.S. Food and Drug Administration (FDA) on the 25th of June 2018 approved Epidiolex oral solution that is essentially cannabidiol or the active component of marijuana or cannabis. As of now the drug is approved for use in two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome. The approval comes for individuals over two years of age.

28 Jun 2018

FDA approves new marijuana-based drug to treat rare and severe forms of epilepsy

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

25 Jun 2018

FDA approves marijuana based medication for epilepsy treatment

An advisory panel from the United States Food and Drug Administration (FDA) has recommended the approval of a novel epilepsy drug that is made up of ingredients from marijuana. The agency normally follows the recommendations of the advisory panels regarding approvals and rejections of applications of new drugs. The recommendation statement came yesterday (19th April 2018).

19 Apr 2018

Cannabidiol shows promise to reduce seizures for people with difficult-to-treat epilepsy

Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy, according to new information released today from a large scale controlled clinical study that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.

19 Apr 2017

Mylan releases generic version of Felbatol Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda Pharms' Felbatol Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product.

19 Jan 2016

New technology benefits child suffering from severe form of epilepsy

Brittany Brown has watched her daughter, Amaree, 6, struggle with hundreds of seizures every day for the past six years. Yes, hundreds. Every day.

26 Sep 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015